butabarbital will minimize the level or impact of atorvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
Phenobarbital appears to interfere Together with the absorption of orally administered griseofulvin, Therefore lowering its blood stage.
butabarbital will decrease the extent or impact of rabeprazole by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
butabarbital will lower the extent or outcome of zolpidem by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Not known.
butabarbital will minimize the extent or influence of nitrendipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Not known.
Generally consult your Health care supplier to make sure the knowledge displayed on this webpage applies to your own circumstances.
Phenobarbital has actually been demonstrated to shorten the fifty percent-lifetime of doxycycline for so long as two months after barbiturate therapy is discontinued. This mechanism is most likely with the induction of hepatic microsomal enzymes that metabolize the antibiotic.
butabarbital will lower the level or result of tolbutamide by affecting hepatic enzyme CYP2C9/ten metabolism. Slight/Significance Unidentified.
butabarbital will lower the extent or influence of estropipate by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
The next adverse drug reactions and incidences are derived from solution labeling Until normally specified.
The result of barbiturates to the metabolism of phenytoin appears for being variable. Some Butabarbital Sodium investigators report an accelerating influence, while some report no impact. Because the impact of barbiturates within the metabolism of phenytoin will not be predictable, phenytoin and barbiturate blood levels should be monitored much more often if these medicines are provided concurrently.
butabarbital will lessen the level or impact of meloxicam by impacting hepatic enzyme CYP2C9/ten metabolism. Slight/Significance Mysterious.
The next adverse reactions are observed with the use of barbiturates in hospitalized individuals. For the reason that this kind of people might be a lot less aware about sure of the milder adverse outcomes of barbiturates, the incidence of such reactions might be considerably bigger in fully ambulatory people.
butabarbital will decrease the extent or outcome of alosetron by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unidentified.